Combined oxidative phosphorylation defect type 23 is a rare genetic mitochondrial disorder. It affects how cells make energy and can cause poor growth, feeding problems, low muscle tone, and developmental delays. Many people with Combined oxidative phosphorylation defect type 23 show signs in infancy and features can involve the brain, heart, liver, and muscles. The condition is lifelong and severity varies, and early symptoms of Combined oxidative phosphorylation defect type 23 may include low energy and trouble gaining weight. Treatment focuses on supportive care, nutrition, seizure control, and organ-specific management, and outcomes range widely depending on how severe the complications are.
Overview
Combined oxidative phosphorylation defect type 23Symptoms
Combined oxidative phosphorylation defect type 23 is usually noticed in early infancy with poor feeding, weak muscle tone, and delayed development. Many develop seizures, breathing difficulties, and lactic acidosis. Doctors may find heart problems, liver issues, and failure to thrive.
Outlook and prognosis
Many living with Combined oxidative phosphorylation defect type 23 face serious, early-onset challenges that can affect muscles, brain development, and growth. Prognosis varies by severity and organ involvement. Early diagnosis, supportive therapies, and proactive complication management can improve comfort, function, and survival.
Causes and risk factors
Combined oxidative phosphorylation defect type 23 stems from inherited changes in a nuclear gene disrupting mitochondrial energy production. Usually autosomal recessive; risk rises when both parents are carriers or are related. Illness, fasting, or other stressors may intensify early-life effects.
Genetic influences
Genetics are central in Combined oxidative phosphorylation defect type 23. Pathogenic variants in nuclear genes disrupt mitochondrial energy production, driving the condition and its severity. Inheritance is usually autosomal recessive, so carrier testing and family counseling can be important.
Diagnosis
Doctors review clinical features and metabolic results, then confirm with genetic tests. Muscle or skin biopsy with enzyme studies can support diagnosis. Imaging and organ tests assess involvement and guide genetic diagnosis of Combined oxidative phosphorylation defect type 23.
Treatment and drugs
Treatment for Combined oxidative phosphorylation defect type 23 focuses on supporting energy production, managing symptoms, and preventing complications. Care often includes high-calorie nutrition, vitamins or cofactors (like riboflavin or CoQ10), seizure control, infection prevention, and physical, occupational, and feeding therapies. A coordinated metabolic and neurology team tailors plans, monitors organ function, and adjusts supports during illness or surgery.
Symptoms
Families often first notice low energy, feeding struggles, or slow developmental milestones in infancy or early childhood. Early features of Combined oxidative phosphorylation defect type 23 may include low muscle tone, poor weight gain, and delays in movement or speech. Features vary from person to person and can change over time. Some people also develop seizures, breathing problems, or heart issues, especially during illness when the body's energy needs rise.
Rolling, sitting, standing, or first words may come later than expected. Therapies like physical, occupational, and speech therapy can help build skills over time. Progress is possible but may be slower.
Babies may feel floppy and have trouble holding up the head. This can make feeding, fine motor tasks, and later walking more tiring. In Combined oxidative phosphorylation defect type 23, low tone often appears early.
Weak suck, trouble coordinating swallowing, or reflux can affect feeding. Poor intake may lead to slow weight gain and dehydration. Some children with Combined oxidative phosphorylation defect type 23 need feeding support, such as thickened feeds or a feeding tube.
During infections or fasting, acid can build up in the blood from energy shortages. This may show up as fast breathing, vomiting, belly pain, or unusual sleepiness. It can be urgent and needs prompt medical care.
How people usually first notice Combined oxidative phosphorylation defect type 23?
Many families first notice something is off in the newborn period or early infancy: a baby who seems unusually sleepy or weak, has trouble feeding, or isn’t growing as expected. Doctors may pick up early red flags such as low muscle tone, persistent lactic acidosis on blood tests, or signs of heart or liver involvement, which prompt evaluation for a mitochondrial disorder, including the first signs of Combined oxidative phosphorylation defect type 23. In some cases, the condition is first noticed after an intercurrent illness triggers sudden worsening—poor feeding, vomiting, rapid breathing, or seizures—leading to hospital testing that uncovers the metabolic problem.
Types of Combined oxidative phosphorylation defect type 23
Combined oxidative phosphorylation defect type 23 is a rare genetic condition present from birth. There are no widely accepted subtypes or clinical variants defined by different genes or enzyme defects under this exact name. Because of that, discussions about types of Combined oxidative phosphorylation defect type 23 usually focus on how symptoms vary in severity rather than distinct variants. If you’re looking for types of Combined oxidative phosphorylation defect type 23 across the medical literature, you won’t find separate, consensus variants listed.
No recognized variants
There are currently no distinct, widely agreed-upon variants of Combined oxidative phosphorylation defect type 23. Differences between people usually reflect severity and organ involvement rather than separate types.
What genetics can tell you about symptoms
Some people with this condition develop low muscle tone, feeding problems, seizures, and delayed milestones because gene changes disrupt how mitochondria make cellular energy. Variants in genes like ELAC2 or TRMT10C can especially affect brain and heart, leading to cardiomyopathy and neurologic symptoms.
Causes and risk factors
Most cases are caused by inherited changes in a gene that disrupts how mitochondria make energy.
Combined oxidative phosphorylation defect type 23 is usually autosomal recessive, and both parents are typically carriers without symptoms.
Risk factors for Combined oxidative phosphorylation defect type 23 include having carrier parents, a known family history, or parents who are related by blood.
Illnesses with fever, fasting, dehydration, hard exertion, or certain medicines can increase energy demand and may worsen symptoms.
Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Combined oxidative phosphorylation defect type 23 is present from birth, so risks mostly relate to what happens around conception and during pregnancy. Awareness of both biological and environmental influences helps you feel prepared. Research on this specific condition is limited, but some factors are known to raise the chance of congenital problems in the cell’s energy system (mitochondria). Here’s what’s known about environmental and biological risk factors for Combined oxidative phosphorylation defect type 23.
Older paternal age is linked to a higher chance of new biological changes at conception. This can increase the likelihood of rare, present-from-birth conditions. For Combined oxidative phosphorylation defect type 23, the absolute risk remains very low.
Older maternal age is associated with more age-related changes in eggs. That slightly raises the overall risk of rare congenital conditions. The chance of this affecting Combined oxidative phosphorylation defect type 23 is still small.
Health issues before pregnancy, such as poorly controlled diabetes, can affect the early pregnancy environment. This has been linked with higher risks of some congenital conditions. A specific link to defects in cell energy production is less clear.
Significant ionizing radiation exposure very early in pregnancy can damage rapidly dividing cells, including their energy-making parts. This could slightly increase the chance of congenital problems in energy pathways. Such exposures are uncommon, and medical imaging typically uses low doses designed to limit fetal risk.
Genetic risk factors
Most cases trace back to harmful changes in the GTPBP3 gene, which helps mitochondria assemble energy-making proteins. Some risk factors are inherited through our genes. Understanding the genetic causes of Combined oxidative phosphorylation defect type 23 can guide testing and help families plan.
GTPBP3 gene variants: Most people with this condition have harmful changes in both copies of the GTPBP3 gene. This gene helps modify mitochondrial transfer RNAs so cells can build energy-making proteins. Disruption of this step can lower the activity of several energy complexes at once.
Autosomal recessive pattern: It takes two faulty copies—one from each parent—to cause disease. Parents are usually healthy carriers. Each pregnancy has a 25% (1 in 4) chance of a child with Combined oxidative phosphorylation defect type 23.
Carrier status in family: Unaffected full siblings have a high chance of being carriers if a brother or sister is affected. Identifying carrier relatives clarifies who could pass the variant to future children.
Parental relatedness: When parents are related by blood, they are more likely to share the same rare variant. This raises the chance of an autosomal recessive condition appearing in their children.
Variant effect matters: Changes that severely disrupt GTPBP3 function can lead to earlier or more pronounced features. Milder changes may allow later onset or a less severe course.
Not mtDNA inherited: Combined oxidative phosphorylation defect type 23 is caused by changes in a nuclear gene, not mitochondrial DNA. It affects people of any sex equally, and it does not follow maternal-only inheritance.
Overlapping gene pathways: Changes in other mitochondrial tRNA-modifying genes, such as MTO1 or TRMU, can cause similar problems but are distinct conditions. This helps explain why early symptoms of Combined oxidative phosphorylation defect type 23 can resemble other mitochondrial disorders.
Molecular confirmation: Genetic testing can identify the family’s GTPBP3 variants and confirm the diagnosis. Once known, those variants can be used for targeted carrier testing and options like prenatal or preimplantation testing.
Lifestyle risk factors
This is a genetic mitochondrial disorder; lifestyle habits do not cause it, but they can shape day-to-day energy, symptoms, and complications. Choices that strain energy supply or oxygen delivery can worsen fatigue, lactic acidosis, and muscle injury, while supportive routines may improve function. Understanding how lifestyle affects Combined oxidative phosphorylation defect type 23 can help tailor daily habits to reduce setbacks.
Long gaps without food can trigger hypoglycemia and lactic acidosis in an energy-limited system. Regular meals and snacks help stabilize energy and reduce metabolic crashes.
All‑out or unaccustomed bursts of exercise can precipitate severe fatigue, muscle breakdown, or rhabdomyolysis. Pacing and avoiding anaerobic surges reduce lactate buildup and post-exertional crashes.
Prolonged inactivity weakens muscles and worsens exercise intolerance in mitochondrial myopathy. Gentle, regular aerobic activity can improve endurance and daily function.
High temperatures raise metabolic demand and can worsen fatigue, dizziness, and dysautonomia. Cooling strategies and avoiding hot environments help prevent energy crashes.
Risk prevention
Combined oxidative phosphorylation defect type 23 is a genetic mitochondrial condition, so there isn’t a way to fully prevent it. Prevention focuses on lowering complications, avoiding metabolic stress, and catching problems early. Different people need different prevention strategies—there’s no single formula. The steps below can help reduce hospitalizations and protect day-to-day energy.
A genetic counselor can explain inheritance, carrier testing, and reproductive options. This helps families understand risks for future children and plan screening in pregnancy if desired.
Routine vaccines lower the chance of infections that can trigger metabolic crashes. Staying current helps people with Combined oxidative phosphorylation defect type 23 avoid preventable complications.
During illness, avoid prolonged fasting and follow a doctor-provided plan for fluids and carbohydrates. Promptly contact your care team if vomiting, dehydration, or fast breathing develops with this condition.
Some drugs can stress mitochondria, so review all medicines and supplements with your clinician. For people with Combined oxidative phosphorylation defect type 23, certain anti-seizure drugs and high-dose acetaminophen may need special caution or alternatives.
Transmission
Combined oxidative phosphorylation defect type 23 is not contagious; it doesn’t spread through touch, air, food, or blood. It follows an autosomal recessive pattern, meaning a child is affected only when they inherit two non-working copies of the same gene—one from each parent, who are usually healthy carriers. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child with no gene change. A new gene change can appear for the first time in a child, but this is uncommon. A genetics professional can explain how Combined oxidative phosphorylation defect type 23 is inherited and discuss carrier or prenatal testing options for your family.
When to test your genes
Consider genetic testing if there’s a family history of early, unexplained neurologic decline, metabolic crises, or infant losses suggestive of mitochondrial disease, especially in related pregnancies. Test sooner if a child shows failure to thrive, low muscle tone, lactic acidosis, or multisystem involvement. Results can guide care, reproductive planning, and screening of relatives.
Diagnosis
Combined oxidative phosphorylation defect type 23 is a rare genetic condition tied to how the body’s cells make energy, so clues often show up in infancy or early childhood as feeding problems, low muscle tone, or developmental delays. Doctors usually begin by looking at patterns of symptoms and exam findings, then confirm with targeted tests. The genetic diagnosis of Combined oxidative phosphorylation defect type 23 is typically made with DNA testing, supported by lab and imaging results that point to a mitochondrial energy problem.
Providers look for early signs such as poor feeding, low muscle tone, slow development, seizures, or breathing problems. Together, these patterns suggest a disorder affecting energy production.
Blood and sometimes spinal fluid are checked for lactate, pyruvate, blood gases, and basic chemistries. High lactate or related changes can support a mitochondrial cause, though results can vary day to day.
A mitochondrial or neurometabolic gene panel, or whole exome/genome sequencing, can identify the exact gene change. Finding a disease‑causing variant confirms the diagnosis and can guide family planning.
Testing respiratory chain enzyme activity in muscle or skin fibroblasts can show which parts of the energy pathway are underperforming. These results help connect symptoms to a specific mitochondrial defect.
Stages of Combined oxidative phosphorylation defect type 23
Combined oxidative phosphorylation defect type 23 does not have defined progression stages. This rare mitochondrial condition can look very different from one person to another and may change over time depending on which organs are affected and how severely. Different tests may be suggested to help confirm what’s going on, such as blood and urine checks, heart and brain imaging, electrical studies of muscles and nerves, and sometimes a muscle biopsy; genetic testing often identifies the gene change. Ongoing care usually involves regular reviews with specialists to follow growth, movement, feeding, breathing, and heart health, and to watch for early symptoms of Combined oxidative phosphorylation defect type 23.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many living with Combined oxidative phosphorylation defect type 23, early symptoms of Combined oxidative phosphorylation defect type 23 appear in infancy, often with feeding difficulty, low muscle tone, and poor weight gain. Some children develop heart or liver complications, seizures, or breathing problems, which can raise the risk of serious illness. The outlook is not the same for everyone, but children with severe organ involvement—especially early heart failure or uncontrollable seizures—may face a shortened lifespan.
Others have a slower course with fewer organ issues and can live into later childhood or beyond with close monitoring and supportive care. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Nutrition support, seizure control, infection prevention, and careful management of heart and liver health can reduce hospitalizations and may improve day-to-day stamina. When doctors talk about “remission,” they mean symptoms have eased or disappeared for a while, but with mitochondrial conditions like this, ups and downs are common and setbacks can be triggered by illness or fasting.
Mortality varies widely because the condition ranges from mild to very severe; the highest risk is in those with early multi‑organ disease. With ongoing care, many people maintain better energy, growth, and comfort even if the condition remains life‑limiting. Genetic testing can sometimes provide more insight into prognosis, but not everyone with the same gene change will have the same outlook. Talk with your doctor about what your personal outlook might look like, and ask about plans for emergencies, nutrition during illnesses, and ways to avoid triggers that can worsen symptoms.
Long-term effects
Combined oxidative phosphorylation defect type 23 can affect multiple organs that rely on high energy, especially the heart, brain, and muscles. Long-term effects vary widely, depending on when it starts and which organs are most involved. Many families first notice early symptoms of Combined oxidative phosphorylation defect type 23 in infancy or early childhood, and the course can range from severe to more slowly evolving. Doctors often watch growth, motor skills, vision, hearing, and heart function over time to understand the outlook.
The heart may thicken or weaken over time, leading to cardiomyopathy. This can raise the risk of heart rhythm issues or heart failure.
The brain can be affected, with encephalopathy or seizures in some. For many, this can mean long-term differences in learning, attention, or coordination.
Motor milestones like sitting, standing, or walking may arrive later than expected. Speech and fine-motor skills can also progress more slowly.
Low muscle tone and easy fatigue can persist. This may limit endurance for play, school activities, or work in adulthood.
How is it to live with Combined oxidative phosphorylation defect type 23?
Living with Combined oxidative phosphorylation defect type 23 often means navigating significant fatigue, feeding difficulties, and muscle weakness from infancy, with medical appointments and therapies becoming part of everyday routine. Many families coordinate medications, nutritional support, and mobility aids, and they plan days around energy levels to prevent overexertion. For parents, siblings, and caregivers, the impact can be intense—learning specialized care, adjusting work and school schedules, and leaning on respite services and support networks to sustain balance. Even with these challenges, clear care plans, early therapies, and honest communication within the family can help people carve out routines that protect comfort, dignity, and connection.
Treatment and drugs
Treatment for Combined oxidative phosphorylation defect type 23 focuses on easing symptoms, supporting energy needs, and preventing complications, since there’s currently no cure. Care teams often use a mix of high-calorie nutrition, vitamins and cofactors commonly used in mitochondrial care (such as riboflavin, coenzyme Q10, and L‑carnitine), careful blood sugar management, and prompt treatment of infections; doctors sometimes recommend a combination of lifestyle changes and drugs. Physical, occupational, and speech therapies help maintain strength, movement, and feeding, while seizure medicines, heart medicines, or breathing support may be added based on features seen in each person. During illness or surgery, people with Combined oxidative phosphorylation defect type 23 may need IV fluids with glucose, temperature control, and avoidance of medicines that can stress mitochondria. Finding the right therapy can take some time, so regular follow‑up with a metabolic or mitochondrial specialist is important to adjust care as needs change.
Non-drug treatment
Combined oxidative phosphorylation defect type 23 can affect energy in many organs, so day-to-day care often focuses on comfort, growth, and development. Alongside medicines, non-drug therapies can support breathing, feeding, movement, and communication. Plans are tailored to age and which organs are involved, and they often change over time. Early symptoms of Combined oxidative phosphorylation defect type 23 may be helped by supportive care that reduces fatigue and prevents complications.
A registered dietitian can tailor calories and protein to support growth and reduce fatigue. Small, frequent meals and avoiding long fasts may help stabilize energy.
If swallowing is hard or weight gain stalls, a feeding tube can safely deliver nutrition. Speech and feeding therapists can teach safer swallowing strategies.
Gentle, regular movement helps maintain joint range, strength, and head and trunk control. Therapists also work on breathing posture and clearing secretions through positioning.
Training focuses on daily activities like dressing, bathing, and fine hand skills. Adaptive tools can make tasks easier and conserve energy.
Your genes may have an impact on how drugs work for you
Medicines for combined oxidative phosphorylation defect type 23 can work differently depending on variants in genes that affect mitochondria and how the body processes drugs. Pharmacogenetic testing may guide dosing or choice of supportive therapies, aiming to improve benefit and reduce side effects.
Pharmacological treatments
For Combined oxidative phosphorylation defect type 23, medicines aim to support energy production, manage seizures or heart problems, and correct lactic acidosis rather than cure the condition. Early symptoms of Combined oxidative phosphorylation defect type 23 can include poor feeding, low muscle tone, or seizures, so treatment often centers on mitochondrial “fuel” and symptom control. Not everyone responds to the same medication in the same way. Your team will individualize choices and adjust over time based on response and side effects.
May support energy production in cells under mitochondrial stress. Often tried first in a mitochondrial supplement plan due to a favorable safety profile.
Can help enzymes involved in energy metabolism work more efficiently. A harmless bright-yellow urine color is common with this vitamin.
Sometimes used to reduce lactic buildup and support carbohydrate processing. Generally well tolerated since excess is excreted in urine.
Helps shuttle fatty acids into mitochondria for energy, which may ease fatigue. Can cause mild stomach upset or a fishy body odor in some people.
Genetic influences
Combined oxidative phosphorylation defect type 23 is most often caused by changes in a nuclear gene that helps the body build and run mitochondria, the parts of the cell that make energy. These changes are inherited in an autosomal recessive pattern, meaning both parents usually carry one copy of the gene change and are healthy themselves. A “carrier” means you have the gene change but may not show symptoms. When two carriers have a child, each pregnancy has a 25% chance of the child inheriting both copies and developing Combined oxidative phosphorylation defect type 23. Because carriers are typically well, family history can look silent, and early symptoms of Combined oxidative phosphorylation defect type 23 often appear in infancy without much warning, though severity and timing can vary. Genetic testing of blood or saliva can often find the exact gene change, confirm the diagnosis, and guide family planning decisions, including testing for partners or future pregnancies.
Is Combined oxidative phosphorylation defect type 23 genetic?
Genetics are central in Combined oxidative phosphorylation defect type 23. Pathogenic variants in nuclear genes disrupt mitochondrial energy production, driving the condition and its severity. Inheritance is usually autosomal recessive, so carrier testing and family counseling can be important.
Pharmacogenetics—how genetics influence drug effects
Because Combined oxidative phosphorylation defect type 23 stems from changes that impair the cell’s energy factories, treatment choices often focus on protecting mitochondria and avoiding drug stress. Clinicians may avoid or closely monitor medicines known to tax mitochondria or raise the risk of lactic acid build-up—such as valproate for seizures, metformin for diabetes, and certain antibiotics like linezolid. Anesthesia plans, especially prolonged propofol infusions, are also tailored with extra care to prevent low energy states, dehydration, or long fasting that can reduce tolerance.
Genetic testing is often considered when early symptoms of Combined oxidative phosphorylation defect type 23 raise concern for a mitochondrial disorder, because results can guide which medicines are safest and how closely to watch for side effects. Alongside medical history and current medicines, genetic testing can help tailor dosing and flag medicines to avoid. Some people with mitochondrial conditions may be offered trials of vitamins or cofactors, such as riboflavin or coenzyme Q10, though benefits vary by the exact gene change and are not guaranteed. Common pharmacogenetic differences outside the disease gene can also matter; for example, variants that affect drug-processing enzymes may change how your body handles anti-seizure, pain, or mood medicines that people with Combined oxidative phosphorylation defect type 23 sometimes need.
Interactions with other conditions
Illnesses that strain the body—like viral infections with fever, dehydration, or surgery—can make symptoms of Combined oxidative phosphorylation defect type 23 flare, sometimes leading to more fatigue, weakness, or worsening lactic acidosis. When epilepsy is present, certain anti‑seizure medicines that tax mitochondria may aggravate muscle or liver stress, so teams often choose drugs carefully and avoid those with higher mitochondrial risk when possible. Heart or liver involvement from another condition can heighten anesthesia and fasting risks, so advance planning for procedures (extra glucose, careful temperature control, and close monitoring) is important. Digestive problems or malnutrition from any cause can reduce the fuel available to cells and may intensify feeding difficulties; early nutrition support can help steady energy levels and growth.
Some conditions share underlying mechanisms, such as disruptions in the cell’s energy-making pathways, so metabolic or neuromuscular diseases may overlap in families. Respiratory infections can be especially challenging if there is muscle weakness affecting breathing, and even early symptoms of Combined oxidative phosphorylation defect type 23 may seem worse during a chest cold. Medications for other illnesses, including certain antibiotics or anesthesia drugs, may interact with mitochondrial function, so clinicians typically review every prescription with this in mind. If you live with another chronic condition alongside this disorder, coordinated care across specialists helps reduce triggers and keep treatment plans aligned.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants who struggled to gain strength, tired easily with feeding, and developed breathing problems without a clear infection. Families and communities once noticed patterns in which more than one child in a generation became weak early in life, and some did not survive infancy. Doctors later recorded clusters of babies with low muscle tone, enlarged livers, and lactic acidosis—features pointing to a problem with how cells make energy.
From early theories to modern research, the story of Combined oxidative phosphorylation defect type 23 traces a path from bedside observations to the lab bench. Initially understood only through symptoms, later testing revealed that the tiny “power stations” in cells, the mitochondria, were not working well. Clinicians recognized that these children often had multiple organs involved—brain, muscles, heart, and liver—suggesting a common energy pathway at the root. As medical science evolved, specialized blood and spinal fluid tests began to show consistent patterns, including high lactate, which supported a mitochondrial cause.
Advances in genetics transformed the picture. Instead of grouping all mitochondrial disorders together, researchers could pinpoint specific genes that help assemble the cell’s energy-making machinery. For people with Combined oxidative phosphorylation defect type 23, modern sequencing linked their symptoms to changes in a gene needed to build parts of the oxidative phosphorylation system, the final steps cells use to turn food into usable energy. This explained why early symptoms of Combined oxidative phosphorylation defect type 23 often appear in newborns and young infants, when energy demands are high.
Over time, descriptions became more precise. What had been labeled broadly as “mitochondrial disease” was refined into distinct types, each tied to a gene and pathway. This shift didn’t change the day-to-day challenges families faced, but it opened doors to clearer counseling, carrier testing, and more tailored care plans. It also clarified why the condition can vary: different genetic changes in the same gene can act like a dimmer switch, affecting how much the energy system is turned down.
Knowing the condition’s history helps explain today’s approach. Early observations taught clinicians to look beyond a single organ and consider the whole body’s energy needs. Modern tools confirm the diagnosis and guide supportive care, while research networks collect data to better understand outcomes. The journey from careful bedside notes to gene-level answers reflects a larger story in medicine: when a rare condition like Combined oxidative phosphorylation defect type 23 is recognized and named, it becomes easier to study, discuss, and support the people living with it.